15 research outputs found
Single-Polymer Composites (SPCs) : Status and Future Trends
Preparation, properties and applications of single-polymer composites (SPCs), representing an emerging family within the polymeric composite materials, have been surveyed. SPCs were classified in respect to their composition (one- and two-constituents), and preforms (non-consolidated and consolidated). SPCs composed of amorphous or semicrystalline matrices and semicrystalline reinforcements were considered. Methods to widen the temperature difference between the matrix- and reinforcement-giving materials of the same polymer (one-constituent) or same polymer type (two-constituent approach) have been introduced and discussed. Special attention was paid to the unsolved questions related to the interface/interphase in SPCs. It was emphasized that the development of SPCs is fuelled by the need of engineering parts in different applications which have low density and “ultimate” recyclability (i.e. reprocessing via remelting). Recent development of SPCs is supported by novel preform preparation, consolidation and production possibilities
The Role of Molecular Imaging as a Marker of Remyelination and Repair in Multiple Sclerosis
The appearance of new disease-modifying therapies in multiple sclerosis (MS) has revolutionized our ability to fight inflammatory relapses and has immensely improved patients’ quality of life. Although remarkable, this achievement has not carried over into reducing long-term disability. In MS, clinical disability progression can continue relentlessly irrespective of acute inflammation. This “silent” disease progression is the main contributor to long-term clinical disability in MS and results from chronic inflammation, neurodegeneration, and repair failure. Investigating silent disease progression and its underlying mechanisms is a challenge. Standard MRI excels in depicting acute inflammation but lacks the pathophysiological lens required for a more targeted exploration of molecular-based processes. Novel modalities that utilize nuclear magnetic resonance’s ability to display in vivo information on imaging look to bridge this gap. Displaying the CNS through a molecular prism is becoming an undeniable reality. This review will focus on “molecular imaging biomarkers” of disease progression, modalities that can harmoniously depict anatomy and pathophysiology, making them attractive candidates to become the first valid biomarkers of neuroprotection and remyelination
Pregnancy- and lactation-induced osteoporosis: a social-media-based survey
Abstract Background Pregnancy- and lactation-induced osteoporosis (PLO) presenting as spinal fractures is rare, and the spectrum of clinical presentation, risk factors and pathophysiology are incompletely understood. The aim of this study was to delineate clinical parameters, risk factors and osteoporosis-related quality of life (QOL) of women with PLO. Methods Participants of a social-media (WhatsApp) PLO group and mothers of a parents’ WhatsApp group (control group) were offered to fill a questionnaire, including an osteoporosis-related QOL section. The groups were compared using the independent Students t test for numerical variables, and the Chi-square test or Fisher’s exact test for categorical variables. Results Twenty-seven women with PLO and 43 in the control group (aged 36.2 ± 4.7 and 38.8 ± 4.3 years, respectively, p = 0.04) participated. Among women with PLO, more than 5 vertebrae were involved in 13 (48%), 4 vertebrae in 6 (22%), and 3 or fewer vertebrae in 8 (30%). Among the 24 women with relevant data, 21 (88%) had nontraumatic fractures; 3 (13%) women had fractures during pregnancy, and the remaining during the early postpartum period. Diagnosis was delayed for over 16 weeks for 11 (41%) women; 16 (67%) received teriparatide. Significantly lower proportions of women in the PLO group engaged in physical activity over 2 hours/week, before and during pregnancy (37 vs. 67%, p < 0.015 and 11 vs. 44%, p < 0.003, respectively). A lower proportion of the PLO than the control group reported calcium supplementation during pregnancy (7% vs. 30%, p = 0.03) and a higher proportion reported treatment with low-molecular-weight-heparin during pregnancy (p = 0.03). Eighteen (67%) of the PLO group expressed fear of fractures and 15 (56%) fear of falls, compared to none and 2%, respectively, of the control group (p < 0.00001 for both). Conclusions Most of the women with PLO who responded to our survey reported spinal fractures involving multiple vertebrae, delayed diagnosis, and treatment with teriparatide. Compared to a control group, they reported less physical activity and impaired QOL. For this uncommon yet severe condition, a multidisciplinary effort should be exerted for early identification and treatment, to alleviate back pain, prevent subsequent fractures and improve QOL
The Risk of Coronary Heart Disease Associated With Glycosylated Hemoglobin of 6.5% or Greater Is Pronounced in the Haptoglobin 2-2 Genotype
AbstractBackgroundResearch targeting glycosylated hemoglobin A1c (HbA1c) to <6.5% to prevent coronary heart disease (CHD) events has conflicting results. We previously observed the haptoglobin (Hp) Hp2-2 genotype is associated with a ∼10-fold increased CHD risk among individuals with HbA1c ≥6.5%, and thus might be useful in identifying those at high risk of CHD who would benefit from maintaining HbA1c <6.5%.ObjectivesThis study sought to model whether HbA1c ≥ 6.5% in the Hp2-2 genotype is associated with CHD in a prospective case-control study nested within the Health Professionals Follow-Up Study (HPFS).MethodsHbA1c concentration and Hp genotype were determined for 695 incident cases of CHD from 1994 to 2010 and matched control participants. Logistic regression models calculated relative risk (RR) and 95% CI, for the first and second halves of follow-up, adjusting for confounding variables. A dataset from the Nurses’ Health Study served as a replication cohort.ResultsThe prevalence of the Hp2-2 genotype in HPFS was 39%. Compared with HbA1c <6.5%, the RR of CHD for HbA1c ≥6.5% for the Hp2-2 genotype over full follow-up was 3.07 (95% CI: 1.37 to 6.86) to 3.88 (95% CI: 1.31 to 11.52) during the first half of follow-up and 2.16 (95% CI: 0.61 to 7.61) in the second half. The corresponding RRs for the Hp1-1 + Hp2-1 genotypes were: full follow-up, 2.19 (95% CI: 1.14 to 4.24); first half, 1.60 (95% CI: 0.73 to 3.53); and second half, 4.72 (95% CI: 1.26 to 17.65).ConclusionsIn 2 independent cohorts, the risk of CHD associated with HbA1c ≥6.5% is pronounced in the Hp2-2 genotype, particularly in early cases. The Hp2-2 genotype may identify individuals at greatest CHD risk from hyperglycemia
Sedum-dominated green-roofs in a semi-arid region increase CO2 concentrations during the dry season
The Risk of Coronary Heart Disease Associated With Glycosylated Hemoglobin of 6.5% or Greater Is Pronounced in the Haptoglobin 2-2 Genotype
Kiasman opastimen konseptointi
Tämän opinnäytetyön tarkoituksena on suunnitella opastinkonsepti Nykytaiteen museo Kiasmalle. Kiasma on antanut opastimen suunnittelusta toimeksiannon Metropolia Ammattikorkeakoululle. Kiasman tavoitteena on parantaa kävijöiden museokokemusta sillä, että kävijät löytävät kaikkiin museon näyttelytiloihin, ja opastimen tehtävänä on edesauttaa tämän tavoitteen toteutumista.
Suunnittelun lähtökohtana on kehittää opastin olemassa olevien opasteiden rinnalle Kiasmaan. Suunnittelun pohjaksi on valittu palvelumuotoilun menetelmät ja havainnointi. Palvelumuotoilun menetelmänä on käytetty palvelupolkua, joka muodostetaan Kiasman kävijän näkökulmasta. Palvelupolun avulla löydetään Kiasman ongelmakohdat kävijän kulkemiselle. Havainnointia tehtiin tarkkailemalla Kiasmassa kävijöitä ja heidän liikkeitään. Havainnoinnin avulla tarkennetaan, miten kävijät liikkuvat ongelmakohdissa.
Havainnoinnin tuloksia käytetään opastimen konseptoinnissa. Konseptointivaiheessa listataan eri konseptityyppejä opastimelle. Näistä konseptityypeistä karsitaan toimeksiantajan kanssa pisteyttämällä kolme konseptityyppiä. Ideoinnin ja luonnostelun avulla luodaan konseptityypeistä varsinaiset konseptit, joista toimeksiantaja valitsee yhden jatkokehitettäväksi.
Jatkokehityksessä ideoinnin, luonnostelun ja 3D-mallinnuksen lisäksi tehdään hahmomalli, josta voidaan toimeksiantajan päätöksestä jatkaa varsinaisen prototyypin tekemiseen